Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.42 |
| ▸ | NPY1R | P25929 | 9/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.39 |
| ▸ | NPY2R | P49146 | 5/20 | 0.39 |
| ▸ | CAD | P27708 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17015152 | 0.89 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL21879811 | 0.87 | KMT2A (0.42) | NPY4RNPY1RKMT2APOLBNPY5R | |
| SCHEMBL5812127 | 0.86 | SIRT6 (0.43) | NPY4RNPY1RKMT2APOLBNPY5R | |
| SCHEMBL5812133 | 0.86 | SIRT6 (0.43) | NPY4RNPY1RKMT2APOLBNPY5R | |
| SCHEMBL26017775 | 0.85 | KMT2A (0.47) | NPY4RNPY1RKMT2APOLBNPY5R | |
| SCHEMBL5366976 | 0.84 | SIRT6 (0.43) | NPY4RNPY1RKMT2APOLBNPY5R | |
| SCHEMBL4599236 | 0.83 | CAD (0.39) | NPY4RNPY1RKMT2APOLBNPY5R | |
| SCHEMBL27554606 | 0.83 | CAD (0.39) | NPY4RNPY1RKMT2APOLBNPY5R | |
| SCHEMBL27481242 | 0.83 | CAD (0.39) | NPY4RNPY1RKMT2APOLBNPY5R | |
| SCHEMBL8019370 | 0.83 | CAD (0.39) | NPY4RNPY1RKMT2APOLBNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11123304-B2 | Nanoparticles having poly(ester amide) polymer cores as drug delivery vehicles | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11123304-B2 | Nanoparticles having poly(ester amide) polymer cores as drug delivery vehicles | ASGR1, F12, MSR1 | NPY4R 294/4885NPY1R 76/4885KMT2A 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.